title: Advances in regenerative orthopedics.
abstract: Orthopedic injuries are common and a source of much misery and economic stress. Several relevant tissues, such as cartilage, meniscus, and intra-articular ligaments, do not heal. And even bone, which normally regenerates spontaneously, can fail to mend. The regeneration of orthopedic tissues requires 4 key components: cells, morphogenetic signals, scaffolds, and an appropriate mechanical environment. Although differentiated cells from the tissue in question can be used, most cellular research focuses on the use of mesenchymal stem cells. These can be retrieved from many different tissues, and one unresolved question is the degree to which the origin of the cells matters. Embryonic and induced pluripotent stem cells are also under investigation. Morphogenetic signals are most frequently supplied by individual recombinant growth factors or native mixtures provided by, for example, platelet-rich plasma; mesenchymal stem cells are also a rich source of trophic factors. Obstacles to the sustained delivery of individual growth factors can be addressed by gene transfer or smart scaffolds, but we still lack detailed, necessary information on which delivery profiles are needed. Scaffolds may be based on natural products, synthetic materials, or devitalized extracellular matrix. Strategies to combine these components to regenerate tissue can follow traditional tissue engineering practices, but these are costly, cumbersome, and not well suited to treating large numbers of individuals. More expeditious approaches make full use of intrinsic biological processes in vivo to avoid the need for ex vivo expansion of autologous cells and multiple procedures. Clinical translation remains a bottleneck.
authors.affiliation: Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Collaborative Research Center, AO Foundation, Davos, Switzerland. Electronic address: cevans@bidmc.harvard.edu.
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Evans
mesh_terms: D002454:Cell Differentiation / Q000502:physiology*; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D009985:Orthopedics / Q000639:trends*; D012038:Regeneration; D044968:Regenerative Medicine / Q000639:trends*; D023822:Tissue Engineering / Q000379:methods*
keywords: ACI; BMP; DBM; FDA; Food and Drug Administration; GAM; GDF; IVD; MSC; OA; PCL; PDGF; PLA; PRP; TCP; TGF; autologous chondrocyte implantation; bone morphogenetic protein; cDNA; complementary DNA; demineralized bone matrix; gene-activated matrix; growth differentiation factor; iPS; induced pluripotent stem; intervertebral disk; mesenchymal stem cell; osteoarthritis; platelet-derived growth factor; platelet-rich plasma; polycaprolactone; polylactic acid; transforming growth factor; tricalcium phosphate